Seminars in Nuclear Medicine
Volume 31, Issue 1 , Pages 50-61 , January 2001

The role of positron emission tomography in skeletal disease

  • Gary J.R. Cook

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Gary J.R. Cook, MD, Department of Nuclear Medicine, Division of Radiological Sciences, Guys, Kings and St. Thomas' School of Medicine, Kings College, London, England SE1, 9RT.
    • ,
  • Ignac Fogelman

References 

  1. Blau M, Nagler W, Bender MA. A new isotope for bone scanning. J Nucl Med. 1962;3:332–334
  2. Bang S, Baud CA. Topographical distribution of fluoride in iliac bone of a fluoride-treated osteoporotic patient. J Bone Miner Res. 1990;5(suppl 1):S87–S89
  3. Ishiguro K, Nakagaki H, Tsuboi S, et al. Distribution of fluoride in cortical bone of human rib. Calcif Tissue Int. 1993;52:278–282
  4. Narita N, Kato K, Nakagaki H, et al. Distribution of fluoride concentration in the rat's bone. Calcif Tissue Int. 1990;46:200–204
  5. Blau M, Ganatra R, Bender MA. 18 F-fluoride for bone imaging. Sem Nucl Med. 1972;2:31–37
  6. Hawkins RA, Choi Y, Huang SC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633–642
  7. Hoegerle S, Juengling F, Otte A, et al. Combined FDG and [F-18]fluoride whole-body PET: A feasible two-in-one approach to cancer imaging?. Radiology. 1998;209:253–258
  8. Hoh CK, Hawkins RA, Dahlbom M, et al. Whole body skeletal imaging with [18F]fluoride ion and PET. J Comput Assist Tomogr. 1993;17:34–41
  9. Petren-Mallmin M, Andreasson I, Ljunggren , et al. Skeletal metastases from breast cancer: Uptake of 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol. 1998;27:72–76
  10. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381–2389
  11. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40:1623–1629
  12. Messa C, Goodman WG, Hoh CK, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: Correlation with bone histomorphometry. J Clin Endocrinol Metab. 1993;77:949–955
  13. Schiepers C, Nuyts J, Bormans G, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997;38:1970–1976
  14. Schiepers C, Broos P, Miserez M, et al. Measurement of skeletal flow with positron emission tomography and 18F-fluoride in femoral head osteonecrosis. Arch Orthop Trauma Surg. 1998;118:131–135
  15. Cook GJR, Lodge MA, Blake GM, et al. Differences in skeletal kinetics between vertebral and humeral bone measured by 18F-fluoride PET in postmenopausal women. J Bone Miner Res. 2000;15:763–769
  16. Blake GM, Cook GJR, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Sem Nucl Med. 2000;31:28–49
  17. Eastell R, Delmas PD, Hodgson SF, et al. Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab. 1988;67:741–748
  18. Garnero P, Sornay-Rendu E, Chapuy MC, et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11:337–349
  19. Arlot M, Edouard C, Meunier PJ, et al. Impaired osteoblast function in osteoporosis: Comparison between calcium balance and dynamic histomorphometry. Br Med J. 1984;289:517–520
  20. Kelly PJ, Pocock NA, Sambrook PN, et al. Age and menopause-related changes in indices of bone turnover. J Clin Endocrinol Metab. 1989;69:1160–1165
  21. Berding G, Burchert W, van den Hoff J, et al. Evaluation of the incorporation of bone grafts used in maxillofacial surgery with [18F]fluoride ion and dynamic positron emission tomography. Eur J Nucl Med. 1995;22:1133–1140
  22. Piert M, Winter E, Becker GA, et al. Allogenic bone graft viability after hip revision arthroplasty assessed by dynamic [18F]fluoride ion positron emission tomography. Eur J Nucl Med. 1999;26:615–624
  23. Wootton R, Reeve J, Veall N. The clinical measurement of skeletal blood flow. Clin Sci Mol Med. 1976;50:261–268
  24. Fogelman I, Bessent RG, Turner JG, et al. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978;19:270–275
  25. Eastell R, Blumsohn A. The value of biochemical markers of bone turnover in osteoporosis. J Rheumatol. 1997;24:1215–1217
  26. Duan Y, Tabensky A, DeLuca V, et al. The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur. Bone. 1997;21:447–451
  27. Warburg O. On the origin of cancer cells. Science. 1954;123:306–314
  28. Yamamoto T, Seino Y, Fukumoto H, et al. Overexpression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170:223–230
  29. Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med. 1998;25:1244–1247
  30. (abstr) Chung JK, Kim YK, Yoon JK, et al. Diagnostic usefulness of F-18 FDG whole body PET in detection of bony metastases compared to Tc-99m MDP bone scan. J Nucl Med. 1999;40:96
  31. Moon DH, Maddahi J, Silverman DH, et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998;39:431–435
  32. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1991;179:765–770
  33. Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375–3379
  34. Oyama N, Akino H, Suzuki Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999;29:623–629
  35. Sanz G, Robles JE, Gimenez M, et al. Positron emission tomography with 18fluorine-labelled deoxyglucose: Utility in localized and advanced prostate cancer. BJU Int. 1999;84:1028–1031
  36. Shreve PD, Grossman HB, Gross MD, et al. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996;199:751–756
  37. Yeh SD, Imbriaco M, Larson SM, et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol. 1996;23:693–697
  38. Galasko CSB. In: Skeletal Metastases. London: Butterworths; 1986;
  39. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995;36:1625–1632
  40. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med. 1999;40:1407–1413
  41. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340–3346
  42. Moog F, Bangerter M, Kotzerke J, et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16:603–609
  43. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation. Sem Nucl Med. 1996;26:308–314
  44. Hollinger EF, Alibazoglu H, Ali A, et al. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1998;23:93–98
  45. Eary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res. 1998;4:1215–1220
  46. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med. 1998;39:250–254
  47. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med. 1988;29:181–186
  48. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med. 1991;32:1508–1512
  49. Kole AC, Nieweg OE, Hoekstra HJ, et al. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med. 1998;39:810–815
  50. Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999;40:1637–1643
  51. Jones DN, McCowage GB, Sostman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. J Nucl Med. 1996;37:1438–1444
  52. Garcia R, Kim EE, Wong FC, et al. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med. 1996;37:1476–1479
  53. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301–1306
  54. Kubota R, Kubota K, Yamada S, et al. Methionine uptake by tumor tissue: A microautoradiographic comparison with FDG. J Nucl Med. 1995;36:484–492
  55. Sugawara Y, Braun DK, Kison PV, et al. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: Preliminary results. Eur J Nucl Med. 1998;25:1238–1243
  56. Zhuang T, Duarte PS, Pourdehand M, et al. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose PET imaging. Clin Nucl Med. 2000;25:281–284
  57. Kalicke T, Schmitz A, Risse JH, et al. Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: Results of histologically confirmed cases. Eur J Nucl Med. 2000;27:524–528
  58. Guhlmann A, Brecht-Krauss D, Suger G, et al. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. J Nucl Med. 1998;39:2145–2152
  59. Guhlmann A, Brecht-Krauss D, Suger G, et al. Chronic osteomyelitis: Detection with FDG PET and correlation with histopathologic findings. Radiology. 1998;206:749–754
  60. Liu RS, Chu LS, Yen SH, et al. Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole. Eur J Nucl Med. 1996;23:1384–1387
  61. 27P Liu RS, Chu LS, Chang CP, et al. Assessment of the outcome of diabetic foot lesions by F-18 fluoromisonidazole PET scan. (abstr) J Nucl Med. 1996;37:
  62. Cook GJ, Maisey MN, Fogelman I. Fluorine-18-FDG PET in Paget's disease of bone. J Nucl Med. 1997;38:1495–1497

PII: S0001-2998(01)80031-3

doi: 10.1053/snuc.2001.18746

Seminars in Nuclear Medicine
Volume 31, Issue 1 , Pages 50-61 , January 2001

Article Tools